WallStSmart

Becton Dickinson and Company (BDX)vsNephros Inc (NEPH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 116126% more annual revenue ($22.23B vs $19.12M). BDX leads profitability with a 5.1% profit margin vs 4.1%. BDX trades at a lower P/E of 25.2x. BDX earns a higher WallStSmart Score of 65/100 (B-).

BDX

Strong Buy

65

out of 100

Grade: B-

Growth: 6.0Profit: 5.0Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.49

NEPH

Avoid

32

out of 100

Grade: F

Growth: 6.0Profit: 4.5Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -10.50
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+9.9%)

Margin of Safety

+9.9%

Fair Value

$200.45

Current Price

$151.16

$49.29 discount

UndervaluedFair: $200.45Overvalued
NEPHUndervalued (+6.9%)

Margin of Safety

+6.9%

Fair Value

$4.34

Current Price

$3.42

$0.92 discount

UndervaluedFair: $4.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX2 strengths · Avg: 8.0/10
Price/BookValuation
1.7x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

NEPH1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

Areas to Watch

BDX4 concerns · Avg: 3.0/10
P/E RatioValuation
25.2x4/10

Moderate valuation

Return on EquityProfitability
4.7%3/10

ROE of 4.7% — below average capital efficiency

Profit MarginProfitability
5.1%3/10

5.1% margin — thin

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

NEPH4 concerns · Avg: 3.0/10
Market CapQuality
$36.80M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
7.3%3/10

ROE of 7.3% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Operating MarginProfitability
1.9%3/10

Operating margin of 1.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Price/Book, EPS Growth. PEG of 1.11 suggests the stock is reasonably priced for its growth.

Bull Case : NEPH

The strongest argument for NEPH centers on Debt/Equity.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin.

Bear Case : NEPH

The primary concerns for NEPH are Market Cap, Return on Equity, Profit Margin. A P/E of 48.4x leaves little room for execution misses. Thin 4.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

NEPH carries more volatility with a beta of 1.50 — expect wider price swings.

NEPH is growing revenue faster at 6.9% — sustainability is the question.

BDX generates stronger free cash flow (546M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BDX scores higher overall (65/100 vs 32/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Nephros Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Nephros, Inc., a commercial stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company is headquartered in South Orange, New Jersey.

Want to dig deeper into these stocks?